NOV 15, 2018 09:00 AM PST

Comprehensive Genomic Profiling Becoming a New Standard-of-Care in Oncology

SPONSORED BY: Illumina
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Medical Officer, Illumina, Inc.
    Biography
      For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

      Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.
    • Clinical Oncology Marketing, Illumina, Inc.
      Biography
        Maude is a specialist in molecular biology applications in oncology, across technologies and platforms. Her experience includes contributing to the FDA-approval of 5 Companion Diagnostic (CDx) molecular assays, creating the global go-to-market strategy for a dozen of CDx at various stages in regulatory approval. Maude has educated pathologists and oncologists in early adoption of technologies that have changed medicine and cancer treatments in the last decade.

      Abstract:

      The value behind a comprehensive assessment of the genomic alterations in a tumor has been consistently increasing with the availability of new therapeutic agents and better predictability of response. The regulatory and reimbursement for this type of assay evolved drastically over the last years. We will discuss how this change in environment provides strong value to adopt comprehensive genomic profiling in today's oncology care.


      Show Resources
      You May Also Like
      FEB 26, 2019 09:00 AM PST
      C.E. CREDITS
      FEB 26, 2019 09:00 AM PST
      DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
      NOV 15, 2018 10:00 AM PST
      C.E. CREDITS
      NOV 15, 2018 10:00 AM PST
      DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
      MAR 26, 2019 02:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAR 26, 2019 02:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
      FEB 27, 2019 08:00 AM PST
      C.E. CREDITS
      FEB 27, 2019 08:00 AM PST
      DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
      OCT 16, 2018 03:00 PM CEST
      C.E. CREDITS
      OCT 16, 2018 03:00 PM CEST
      DATE:  October 16, 2018TIME:  3:00 PM CEST, 6:00 AM PDT This webinar will provide an overview on some pathogens that can be transmitted from mother to fetus du...
      Loading Comments...
      Show Resources